Host Research Group
ES28_NanoBioCel_Jose Luis Pedraz
Jose Luis Pedraz
+34 620473687
https://www.ehu.eus/en/web/nanobiocel/home
Group description
Since 2001, our research group from the Pharmacy and Pharmaceutical Science's Department has been recognized as a University of the Basque Country´s (UPV/EHU) "Consolidated Group" by the Basque Government. The principal investigator is Dr. José Luis Pedraz. The members of the group have an extensive research, academic and management background. The group is made up of three full professors, 3 Associate Professor and 3 Assistant Professors and 15 PhD students. Together
The group is actively involved in relevant research projects in the field of pharmaceutical technology, cell therapy, biomaterials characterisation and, especially, in the design and development of new systems for sustained and controlled release of drugs, peptides, proteins, DNA and cells. In recent years, he has participated and continues to participate in cutting-edge European projects: Organs-on-Chips, tissue engineering, regenerative medicine and 3D bioprinting.
The research group's equipment is part of one of the 29 Spanish Singular Scientific and Technological Infrastructures (ICTS), recognised by the Spanish Ministry of Science and Innovation, through the U10 Drug Formulation of Nanbiosis. Through this infrastructure, complete services are offered to industry and other research groups for the production and characterisation of nanomaterials, biomaterials and systems in biomedicine.
The research group has always maintained a direct relationship with the pharmaceutical industry through research projects. As a result of this work the NanoBioCel group and the Tecnalia Corporation created in November 2018, the Basque Pharma Lab 4.0, with the aim of becoming one of the European leaders in advanced services for the pharmaceutical industry and a benchmark in drug R&D.
During 2021, the Joint Research Lab was created, under the leadership of Jose Luis Pedraz and with the support of the University of the Basque Country , Tecnalia Corporation and Provincial Government of Alava to promote research in 3D printing and 3D Bioprinting. Its objective is Promote research collaboration in the fundamentals of 3D printing and 3D bioprinting, regenerative medicine and tissue engineering.
Keywords
- Drug Delivery
- 3D Bioprinting
- Regenerative Medicine
- Tissue Engineering
- Pulmonar Delivery
- Nanotechnology
- Gene Therapy
Team Description
-
Jose Luis Pedraz (Principal Investigator)
ORCID: https://orcid.org/0000-0002-3938-2267
-
Rosa Hernandez (Research staff)
ORCID: https://orcid.org/0000-0002-3947-409X
-
Manuela Igartua (Research staff)
ORCID: https://orcid.org/0000-0003-0283-7923
-
Gorka Orive (Research staff)
ORCID: https://orcid.org/0000-0002-0773-300X
-
Jon Zarate (Research staff)
ORCID: https://orcid.org/0000-0003-1999-057X
-
Laura Saenz del Burgo (Research staff)
ORCID: https://orcid.org/0000-0002-1766-1361
-
Gustavo Puras (Research staff)
ORCID: https://orcid.org/0000-0002-1536-7601
-
Amaia Esquisabel (Research staff)
ORCID: https://orcid.org/0000-0001-7043-2114
-
Edorta Santos (Research staff)
ORCID: https://orcid.org/0000-0001-7064-4563
Projects
-
Benznidazol and Triazol Research Group for nanomedicine and Innovation on Chagas disease -BERENICE-. Proposal No 305937-1 FP7 Health 2012
Pl: Principal Investigator
Funding Agency*: International
Ongoing: no
Project reference: 7PM-COOP-SCP12/10
-
Diabetes reversing implants with enhanced viability and long-term efficacy-DRIVE-. Proposal No: 645991-2.
Pl: Principal Investigator
Funding Agency*: International
Ongoing: no
Project reference: H2020-IL-NMPB14/03
-
A pilot line for the next generation of smart catheters and implants"-POSITION II. ECSEL Electronic Components and Systems for European Leadership. Proposal No: 2017-2-783132.
Pl: Principal Investigator
Funding Agency*: International
Ongoing: yes
Project reference: This project is managing through CIBER BBN.
-
Open Technology Platforms for medical devices Moore4medical Accelerating Innovation in Microfabricated Medical Devices: Optimization of lyophilization of biopharmaceutical products for their application in microfluidic devices. 866190 H2020 ECSEL 2019- 1.IA-two stage.
Pl: Principal Investigator
Funding Agency*: International
Ongoing: yes
Project reference: H2020 ECSEL JTI
-
3D bioprinted personalised scaffolds for tissue regeneration of ankle joint. TRI-ankle 952981-2.
Pl: Principal Investigator
Funding Agency*: International
Ongoing: yes
Project reference: H2020-Industrial Leader-NMPB
Publications
-
LaFuente-Merchan M, Ruiz-Alonso S, Espona-Noguera A, Galvez-Martin P, López-Ruiz E, Marchal J, López-Donaire M.l, Zabala A, Ciriza J, Saenz-del-Burgo L, Pedraz JL., Development, characterization and sterilization of nanocellulose-alginate-(hyaluronic acid)- bioinks and 3D bioprinted scaffolds for tissue engineering., Materials Science and Engineering: C, 2021
10.1016/j.msec.2021.112160 -
Huguet-Casquero A, Gainza E, Pedraz JL., Towards Green Nanoscience: From extraction to nanoformulation., Biotechnology Advances, 2021
10.1016/j.biotechadv.2020.107657 -
Gurruchaga H, Saenz del Burgo L, Hernandez RM, Orive G, Selden C, Fuller B, Ciriza J, Pedraz JL., Advances in the slow freezing cryopreservation of microencapsulated cells., Journal of Controlled Release, 2018
10.1016/j.jconrel.2018.05.016 -
Mashal M, Attia N, Martínez-Navarrete G, Soto-Sánchez C, Fernández E, Grijalvo S, Eritja R, Puras G, Pedraz JL., Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes., Journal of Controlled Release, 2019
10.1016/j.jconrel.2019.05.010 -
Espona-Noguera A, Etxebarria-Elezgarai J, Saenz Del Burgo L, Cañibano-Hernández A, Gurruchaga H, Blanco FJ, Orive G, Hernández RM, Benito-Lopez F, Ciriza J, Basabe-Desmonts L, Pedraz JL., Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets., International Journal of Pharmaceutics, 2019
10.1016/j.ijpharm.2019.01.058
Research Lines
ADVANCED MATERIALS AND PROCESSES
- Development of scaffolds for tissue engineering and regenerative medicine obtained by conventional techniques and by means of bioprinting techniques in 3D printers and development of bioinks for three-dimensional printing of scaffolds, organs and tissues.
- Design and development of drug delivery systems based on nanomedicine for the administration of DNA protein peptides, vaccines and classic active principles.